Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
This study provides the first prospective evidence supporting the safe use of vericiguat in AdHF patients on chronic levosimendan. However, careful monitoring for hypotension is essential, and titration may be more difficult in this population. Further research is needed to optimise treatment strategies for these high-risk patients.
Authors
- Edoardo Sciatti (ORCID: https://orcid.org/0000-0002-3479-3454)
- Emilia D’Elia (ORCID: https://orcid.org/0000-0002-6682-0074)
- Luca Di Odoardo (ORCID: https://orcid.org/0000-0002-7816-5927)
- Michele Senni (ORCID: https://orcid.org/0000-0001-5502-7882)
- Ottavio Zucchetti (ORCID: https://orcid.org/0000-0003-0564-7578)
Institutions
- Ospedale Papa Giovanni XXIII (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Heart
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1136/heartjnl-2025-326009
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39